Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.

A battle over how to treat childhood obesity is brewing between those in favour and others who warn of the effects on growing bodies ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceuticals for diabetes, oncology, immunology, neuroscience, and other therapeutic areas worldwide.

Analysts have deemed LLY stock a “Strong Buy,” with an average target price of $984.29, indicating an upside potential of 12.1% from Friday’s closing price. Among the 24 analysts covering the stock, ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...